License Agreement (Details Narrative) - USD ($) |
1 Months Ended | 2 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|---|
May 31, 2021 |
May 31, 2020 |
Jun. 30, 2020 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Research and development expense | $ 1,223,776 | $ 715,098 | |||
| Vernalis Development Limited [Member] | |||||
| Research and development expense | $ 150,000 | ||||
| Development milestone payment | $ 29,900,000 | ||||
| Vernalis Development Limited [Member] | IPO [Member] | |||||
| Number of shares of common stock | 192,857 | ||||
| Future milestone payments | $ 1,350,000 | ||||
| Vernalis Development Limited [Member] | Minimum [Member] | |||||
| Marketing authorization amount | 350,000 | ||||
| Sales milestone payments | 10,000,000 | ||||
| Cumulative annual net sales amount | 500,000,000 | ||||
| Vernalis Development Limited [Member] | Maximum [Member] | |||||
| Marketing authorization amount | 3,000,000 | ||||
| Sales milestone payments | 25,000,000 | ||||
| Cumulative annual net sales amount | $ 1,000,000,000 | ||||
| X | ||||||||||
- Definition Cumulative annual net sales amount. No definition available.
|
| X | ||||||||||
- Definition Development milestone payment. No definition available.
|
| X | ||||||||||
- Definition Future milestone payments. No definition available.
|
| X | ||||||||||
- Definition Marketing authorization amount. No definition available.
|
| X | ||||||||||
- Definition Sales milestone payments. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|